Skip to main content
European Commission logo print header

Antibacterial (Nano)medicines Development

Obiettivo

Despite the investment of billions of euros, there has been an inexorable decline in the discovery of new antibiotics over the last decades. In this individual fellowship (IF) application we propose a strategy to develop bacterial histidine-kinase (HK) inhibitors targeted at the catalytic and ATP-biding domain (CA) as novel broad-spectrum antibacterial (nano)medicines. Furthermore, putative mechanism of resistance to HK inhibitors and known antibiotics will be studied and novel antibacterial drug targets will be identified by using transposon insertion mutant libraries (Tn-libraries) to identify mutations involved in intrinsic resistance to antibiotics and/or leading to increased sensitivity to existing antibiotics in multi-drug resistant (MDR) strains.

Meccanismo di finanziamento

MSCA-IF-EF-ST - Standard EF

Coordinatore

WAGENINGEN UNIVERSITY
Contribution nette de l'UE
€ 165 598,80
Indirizzo
DROEVENDAALSESTEEG 4
6708 PB Wageningen
Paesi Bassi

Mostra sulla mappa

Regione
Oost-Nederland Gelderland Veluwe
Tipo di attività
Higher or Secondary Education Establishments
Collegamenti
Costo totale
€ 165 598,80